查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1736700

全球糖化血紅素 A1C 檢測設備市場規模（按技術、最終用戶、產品類型、區域範圍和預測）

Global Hemoglobin A1C Testing Devices Market Size By Technology, By End-User, By Product Type, By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

糖化血紅素A1C檢測設備的市場規模及預測

預計 2024 年血紅素 A1C 檢測設備市場規模將達到 14.5 億美元，到 2032 年將達到 28.9 億美元，2026 年至 2032 年的複合年成長率為 8.97%。

與血糖值儀不同，糖化血紅素 (HbA1c) 檢測設備並非設計用於家用檢測。目前美國唯一獲得 FDA 核准的家用糖化血紅素 (HbA1c)檢測檢測套組。這與血糖儀不同，後者可以方便地在家中進行檢測。

A1C Now 自檢試劑套件是一種指尖採血測試，約 12 分鐘即可出結果。不過，您的血液樣本必須郵寄到實驗室處理，結果會在幾天內送達。此檢驗不適用於孕婦、過去三個月內輸過血的人或患有某些血液疾病的人。

全球糖化血紅素A1C檢測設備市場動態

影響糖化血紅素 A1C 檢測設備市場的關鍵市場動態是：

關鍵市場促進因素

糖尿病盛行率上升：根據國際糖尿病聯盟 (IDF) 的數據，全球糖尿病患者數量正在迅速增加。最新的 IDF 糖尿病地圖集估計，2019 年有 4.63 億成年人（20-79 歲）患有糖尿病。預計到 2045 年，這一數字將上升至 7 億。這種急劇成長是由多種因素造成的，包括人口成長、老化、都市化以及生活方式的改變，例如加工食品消費增加和體力活動減少。糖尿病盛行率的上升是糖化血紅蛋白 (A1c) 檢測設備市場的主要驅動力。

預防性醫療保健日益受到重視：大眾對預防性醫療保健和糖尿病管理意識的不斷提升，推動了糖化血紅蛋白 (HbA1c) 檢測設備在早期發現和介入方面的應用。政府機構和衛生組織正在進行宣傳活動，向公眾宣傳糖尿病預防和早期發現的重要性。這些宣傳活動通常強調 HbA1c 檢測在識別糖尿病風險因素以及進行早期療育以預防或延緩疾病發作方面的作用。

就地檢驗(POCT)：即時檢測 (POCT) 設備的興起正在徹底改變糖化血紅蛋白 (HbA1c) 檢測，它允許在診所、藥房甚至家中獲取結果。這使得患者無需前往檢查室或實驗室抽血，大大提高了檢測的便利性和可近性。與傳統的實驗室分析儀相比，即時檢測 (POCT) 設備通常體積更小、更便攜、更易於使用。即時檢測 (POCT) 設備能夠比傳統的實驗室分析儀更快地提供結果，通常在幾分鐘內即可完成，從而能夠快速做出治療決策並進行調整。

主要問題

糖化血紅蛋白 (HbA1c) 檢測設備和測試的費用：HbA1c 檢測設備和測試的費用對某些患者來說可能是一個重大障礙，尤其是在醫療預算有限且糖尿病管理保險覆蓋不足的新興國家。這可能導致 HbA1c 檢測可近性的差異、糖尿病診斷的延誤，並阻礙有效的疾病管理。

準確度擔憂：儘管準確性已顯著提高，但仍存在一些擔憂，例如血紅蛋白變異和某些藥物等因素可能造成干擾。這可能導致檢測結果不準確、診斷延遲以及不必要的治療調整。製造商正在不斷努力提高 HbA1c 檢測設備的準確性，以最大限度地減少這些干擾因素的影響。

主要趨勢

專注於家用檢測：對便捷易得的糖尿病管理的需求日益成長，推動了家用糖化血紅蛋白 (A1c) 檢測設備的發展。這些設備使患者能夠在家中舒適地檢測糖化血紅蛋白 (HbA1c) 水平，無需頻繁前往檢查室或實驗室。目前，家用 A1c 檢測的普及程度有限，但預計未來幾年將變得更加普及和完善。

與糖尿病管理系統整合：將糖化血紅蛋白 (HbA1c) 檢測設備整合到綜合糖尿病管理系統中已成為一種趨勢。這些系統將糖化血紅蛋白 (HbA1c) 檢測與血糖監測、持續血糖監測 (CGM) 設備、胰島素幫浦和行動應用程式結合。這種數據整合可以更全面地了解患者的糖尿病狀況，並有助於制定個人化治療方案。此外，這些系統還可以為患者提供即時數據分析和回饋，使他們能夠就糖尿病管理做出明智的決策。

目錄

第1章 糖化血紅素A1C檢測設備全球市場介紹

  • 市場概覽
  • 研究範圍
  • 先決條件

第2章執行摘要

第3章：已驗證的市場研究調查方法

  • 資料探勘
  • 驗證
  • 第一手資料
  • 資料來源列表

第4章 糖化血紅素 A1C 檢測設備的全球市場展望

  • 概述
  • 市場動態
    • 驅動程式
    • 限制因素
    • 機會
  • 波特五力模型
  • 價值鏈分析

5. 全球糖化血紅素 A1C 檢測設備市場（依技術）

  • 概述
  • 高效液相層析（HPLC）
  • 免疫測量
  • 硼酸鹽親和層析法
  • 直接酵素法檢測法
  • 其他

第6章全球糖化血紅素 A1C 檢測設備市場（按最終用戶）

  • 概述
  • 醫院
  • 診斷實驗室
  • 學術和研究機構
  • 其他

7. 全球糖化血紅素 A1C 檢測設備市場（依產品類型）

  • 概述
  • 桌上型裝置
  • 照護現場(POC) 設備

8. 全球糖化血紅素 A1C 檢測設備市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 其他
    • 拉丁美洲
    • 中東和非洲

第9章全球糖化血紅素A1C檢測設備市場的競爭格局

  • 概述
  • 各公司市場排名
  • 重點發展策略

第10章 公司簡介

  • Abbott Laboratories
  • Siemens Healthineers
  • F. Hoffmann-La Roche AG
  • Danaher Corporation
  • Bio-Rad Laboratories Inc.
  • Sebia
  • ARKRAY, Inc.
  • Trinity BIoTech

第11章 附錄

  • 相關調查
簡介目錄
Product Code: 40143

Hemoglobin A1C Testing Devices Market Size And Forecast

Hemoglobin A1C Testing Devices Market size was valued at USD 1.45 Billion in 2024 and is projected to reach USD 2.89 Billion by 2032, growing at a CAGR of 8.97% from 2026 to 2032.

Hemoglobin A1C (HbA1c) testing devices are not designed for home testing, unlike blood glucose meters. There is currently only one FDA-approved home A1C test kit available in the United States, the A1C Now Self-Check Kit. This differs from blood glucose meters, which are readily available for home testing.

The A1C Now Self-Check Kit is a finger prick test that provides results in about 12 minutes. However, it requires that the blood sample be mailed to a lab for processing, and you will receive your results in a few days. This test is not intended for people who are pregnant, have been transfused in the past 3 months, or have certain blood conditions.

Global Hemoglobin A1C Testing Devices Market Dynamics

The key market dynamics that are shaping the Hemoglobin A1C Testing Devices Market include:

Key Market Drivers

Rising Diabetes Prevalence: Globally, the number of people with diabetes is on a sharp rise, according to the International Diabetes Federation (IDF). In their latest IDF Diabetes Atlas, they estimate that 463 million adults (aged 20-79 years) were living with diabetes in 2019. This number is projected to rise to 700 million by 2045. This dramatic increase is due to several factors, including population growth, aging, urbanization, and lifestyle changes such as increased consumption of processed foods and decreased physical activity. The rising prevalence of diabetes is a major driver of the Hemoglobin A1c Testing Devices Market.

Increased Focus on Preventive Care: Growing public awareness about preventive healthcare and diabetes management is driving the use of HbA1c testing devices for early detection and intervention. Government agencies and health organizations are launching campaigns to educate the public about the importance of diabetes prevention and early detection. These campaigns often highlight the role of HbA1c testing in identifying diabetes risk factors and enabling early intervention to prevent or delay the onset of the disease.

Point-of-Care Testing (POCT): The rise of POCT devices is revolutionizing HbA1c testing by enabling results to be obtained at clinics, pharmacies, or even at home. This eliminates the need for patients to visit a doctor's office or lab for blood draws, significantly improving convenience and access to testing. POCT devices are typically smaller, portable, and easier to use than traditional laboratory-based analyzers. They can provide results in a much shorter timeframe, often within minutes, allowing for quicker treatment decisions and adjustments.

Key Challenges:

Cost of HbA1c Testing Devices and Tests: The cost of HbA1c testing devices and tests can be a significant barrier for some patients, particularly in developing countries where healthcare budgets are limited and insurance coverage for diabetes management may be lacking. This can lead to disparities in access to HbA1c testing, potentially delaying diabetes diagnosis and hindering effective disease management.

Accuracy Concerns: While accuracy has improved significantly, some concerns remain regarding the potential for interference from certain factors such as hemoglobin variants and certain medications. This can lead to inaccurate test results, potentially causing delays in diagnosis or prompting unnecessary treatment adjustments. Manufacturers are constantly working on improving the accuracy of HbA1c testing devices to minimize the impact of these interfering factors.

Key Trends:

Focus on Home Testing: The growing demand for convenient and accessible diabetes management is driving the development of home A1c testing devices. These devices allow patients to test their HbA1c levels in the comfort of their own homes, eliminating the need for frequent visits to a doctor's office or lab. While currently limited in availability, home A1c testing is expected to become more widespread and sophisticated in the coming years.

Integration with Diabetes Management Systems: There's a trend towards integrating HbA1c testing devices with comprehensive diabetes management systems. These systems combine HbA1c testing with blood glucose monitoring, continuous glucose monitoring (CGM) devices, insulin pumps, and mobile apps. This data integration allows for a more holistic view of a patient's diabetes status and facilitates personalized treatment plans. Additionally, these systems can provide real-time data analysis and feedback to patients, empowering them to make informed decisions about their diabetes management.

Global Hemoglobin A1C Testing Devices Market Regional Analysis

Here is a more detailed regional analysis of the hemoglobin A1C Testing Devices Market:

Asia Pacific:

According to Verified Market Research, Asia Pacific is estimated to dominate the market over the forecast period. The region has the highest number of people living with diabetes globally, driven by factors like population growth, aging demographics, and increasing urbanization. This large and growing pool of potential patients fuels the demand for HbA1c testing devices.

Economic development in many Asian countries is leading to increased healthcare spending and rising disposable incomes. This creates a more favorable market for innovative medical technologies like HbA1c testing devices.

Many Asian governments are launching initiatives to address the growing burden of diabetes. These initiatives often include promoting early detection and management of diabetes, which can lead to increased adoption of HbA1c testing devices.

Manufacturers are developing more affordable HbA1c testing devices to cater to the price-sensitive markets in Asia Pacific.

Europe:

Europe has a well-established market for Hemoglobin A1c testing devices, with a strong presence of leading manufacturers and a well-developed healthcare infrastructure.

There's a growing emphasis on proactive management of chronic diseases like diabetes across Europe. HbA1c testing plays a crucial role in monitoring blood sugar control and allowing for timely adjustments to treatment plans, contributing to this focus.

Reimbursement policies play a significant role in the European market. Manufacturers need to navigate these policies to ensure that their HbA1c testing devices are covered by healthcare systems, which can influence market adoption.

European healthcare systems prioritize high-quality medical devices. This focus on accuracy and reliability can influence purchasing decisions for HbA1c testing devices.

European healthcare systems prioritize cost-effectiveness. Manufacturers need to balance technological advancements with affordability to ensure their HbA1c testing devices are financially viable for healthcare providers.

North America:

North America is a leader in developing and adopting innovative medical technologies. This trend extends to the Hemoglobin A1c Testing Devices Market, with manufacturers in North America at the forefront of developing new and improved HbA1c testing devices.

North American countries have some of the highest healthcare expenditures globally. This allows for greater investment in new technologies like HbA1c testing devices.

Public health initiatives and campaigns in North America have significantly increased awareness about diabetes and the importance of early detection. This growing awareness fuels the demand for HbA1c testing as a tool for early diagnosis and risk assessment.

The United States, in particular, has one of the highest healthcare expenditures globally. This allows for greater investment in new technologies like HbA1c testing devices, accelerating market growth.

Global Hemoglobin A1C Testing Devices Market: Segmentation Analysis

The Global Haemoglobin A1C Testing Devices Market is segmented based on Technology, End-User, Product Type, And Geography.

Haemoglobin A1C Testing Devices Market, By Technology

  • High-Performance Liquid Chromatography (HPLC)
  • Immunoassay
  • Boronate Affinity Chromatography
  • Direct Enzymatic Assay
  • Others

Based on Technology Type, the market is segmented into High-Performance Liquid Chromatography (HPLC), Immunoassay, Boronate Affinity Chromatography, Direct Enzymatic Assay, and Others. The High-Performance Liquid Chromatography (HPLC) segment is estimated to exhibit the highest growth within the apparel market due to This dominance stems from its exceptional accuracy and reproducibility in measuring HbA1c levels. HPLC separates various blood components based on their unique properties, allowing for precise isolation and quantification of HbA1c. While other technologies may be emerging, HPLC's established performance makes it the current gold standard for HbA1c testing in laboratories.

Haemoglobin A1C Testing Devices Market, By End-User

  • Hospitals
  • Diagnostic Laboratories
  • Academic & Research Institutes
  • Others

Based on End users, the market is segmented into Hospitals, Diagnostic Laboratories, Academic & Research Institutes, and Others. The hospital segment is estimated to dominate the apparel market. This is because hospitals manage a high volume of patients, including those with diabetes or at risk of developing it. HbA1c testing plays a crucial role in both diagnosing diabetes and monitoring blood sugar control in hospitalized patients. Additionally, hospitals often have the resources to invest in a wider range of HbA1c testing devices, including advanced laboratory-based analyzers and point-of-care devices for faster results.

Haemoglobin A1C Testing Devices Market, By Product Type

  • Bench-top Devices
  • Point-of-Care (POC) Devices

Based on the Product type, the market is divided into Bench-top Devices, Point-of-Care (POC) Devices. The bench-top devices segment is estimated to dominate the global market. These are laboratory-based instruments offering high accuracy and throughput, ideal for large-scale processing of blood samples in hospitals and diagnostic labs. However, the market is shifting toward Point-of-Care (POC) devices. These are smaller, portable devices designed for use in clinics, pharmacies, and even at home. POC devices offer faster turnaround times and greater convenience for patients and healthcare providers. As technology advances and affordability improves, POC devices are expected to capture a larger share of the market in the coming years.

Key Players

  • The "Hemoglobin A1C Testing Devices Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Abbott Laboratories, Siemens Healthineers, F. Hoffmann-La Roche AG, Danaher Corporation, Bio-Rad Laboratories, Inc., Sebia, Tosoh Bioscience, ARKRAY, Inc., and Trinity Biotech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Hemoglobin A1C Testing Devices Market Recent Developments
  • In 2024, Trivitron Healthcare introduced the NANO H5 and NANO H110, which are advanced HPLC-based diagnostic solutions for HbA1c testing that provide results in about 130 seconds.
  • In 2024, Abbott Laboratories offers the Afinion(TM) HbA1c Dx assay, a point-of-care device that delivers rapid and accurate results

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET

  • 1.1 Overview of the Market
  • 1.2 Scope of Report
  • 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 3.1 Data Mining
  • 3.2 Validation
  • 3.3 Primary Interviews
  • 3.4 List of Data Sources

4 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET OUTLOOK

  • 4.1 Overview
  • 4.2 Market Dynamics
    • 4.2.1 Drivers
    • 4.2.2 Restraints
    • 4.2.3 Opportunities
  • 4.3 Porters Five Force Model
  • 4.4 Value Chain Analysis

5 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY TECHNOLOGY

  • 5.1 Overview
  • 5.2 High-Performance Liquid Chromatography (HPLC)
  • 5.3 Immunoassay
  • 5.4 Boronate Affinity Chromatography
  • 5.5 Direct Enzymatic Assay
  • 5.6 Others

6 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY END-USER

  • 6.1 Overview
  • 6.2 Hospitals
  • 6.3 Diagnostic Laboratories
  • 6.4 Academic & Research Institutes
  • 6.5 Others

7 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY PRODUCT TYPE

  • 7.1 Overview
  • 7.2 Bench-top Devices
  • 7.3 Point-of-Care (POC) Devices

8 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET, BY GEOGRAPHY

  • 8.1 Overview
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 U.K.
    • 8.3.3 France
    • 8.3.4 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Rest of Asia Pacific
  • 8.5 Rest of the World
    • 8.5.1 Latin America
    • 8.5.2 Middle East & Africa

9 GLOBAL HEMOGLOBIN A1C TESTING DEVICES MARKET COMPETITIVE LANDSCAPE

  • 9.1 Overview
  • 9.2 Company Market Ranking
  • 9.3 Key Development Strategies

10 COMPANY PROFILES

  • 10.1 Abbott Laboratories
    • 10.1.1 Overview
    • 10.1.2 Financial Performance
    • 10.1.3 Product Outlook
    • 10.1.4 Key Developments
  • 10.2 Siemens Healthineers
    • 10.2.1 Overview
    • 10.2.2 Financial Performance
    • 10.2.3 Product Outlook
    • 10.2.4 Key Developments
  • 10.3 F. Hoffmann-La Roche AG
    • 10.3.1 Overview
    • 10.3.2 Financial Performance
    • 10.3.3 Product Outlook
    • 10.3.4 Key Developments
  • 10.4 Danaher Corporation
    • 10.4.1 Overview
    • 10.4.2 Financial Performance
    • 10.4.3 Product Outlook
    • 10.4.4 Key Developments
  • 10.5 Bio-Rad Laboratories Inc.
    • 10.5.1 Overview
    • 10.5.2 Financial Performance
    • 10.5.3 Product Outlook
    • 10.5.4 Key Developments
  • 10.6 Sebia
    • 10.6.1 Overview
    • 10.6.2 Financial Performance
    • 10.6.3 Product Outlook
    • 10.6.4 Key Developments
  • 10.7 ARKRAY, Inc.
    • 10.7.1 Overview
    • 10.7.2 Financial Performance
    • 10.7.3 Product Outlook
    • 10.7.4 Key Developments
  • 10.8 Trinity Biotech
    • 10.8.1 Overview
    • 10.8.2 Financial Performance
    • 10.8.3 Product Outlook
    • 10.8.4 Key Developments

11 Appendix

  • 11.1 Related Research